<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1365-2125</journal-id>
<journal-id journal-id-type="publisher-id">BCP</journal-id>
<journal-title-group>
<journal-title>British Journal of Clinical Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-5251</issn>
<issn pub-type="epub">1365-2125</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30290005</article-id>
<article-id pub-id-type="pmc">6303203</article-id>
<article-id pub-id-type="doi">10.1111/bcp.13780</article-id>
<article-id pub-id-type="publisher-id">BCP13780</article-id>
<article-id pub-id-type="other">RC-00631-17.R2</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth</article-title>
<alt-title alt-title-type="right-running-head">Metformin and suppression of tumour growth</alt-title>
<alt-title alt-title-type="left-running-head">S. Amin et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="bcp13780-cr-0001">
<name>
<surname>Amin</surname>
<given-names>Sam</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2688-2529</contrib-id>
<address>
<email>sam.amin.14@ucl.ac.uk</email>
</address>
<xref ref-type="aff" rid="bcp13780-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bcp13780-cr-0002">
<name>
<surname>Lux</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="bcp13780-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bcp13780-cr-0003">
<name>
<surname>O'Callaghan</surname>
<given-names>Finbar</given-names>
</name>
<xref ref-type="aff" rid="bcp13780-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bcp13780-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Paediatric Neurologist</named-content>
<institution>University Hospitals Bristol</institution>
<named-content content-type="street">Upper Maudlin Street Centre Level 6</named-content>
<named-content content-type="city">Bristol</named-content>
<named-content content-type="post-code">BS28AE</named-content>
<country country="GB">UK</country>
</aff>
<aff id="bcp13780-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Institute of Child Health</named-content>
<institution>University College London</institution>
<named-content content-type="city">London</named-content>
<named-content content-type="post-code">WC1N 1EH</named-content>
<country country="GB">UK</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence<break></break>
Sam Amin, Paediatric Neurologist, University Hospitals Bristol, Upper Maudlin Street Centre Level 6, Bristol BS2 8AE, UK.<break></break>
E‐mail: <email>sam.amin.14@ucl.ac.uk</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<volume>85</volume>
<issue>1</issue>
<issue-id pub-id-type="doi">10.1111/bcp.v85.1</issue-id>
<fpage>37</fpage>
<lpage>46</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BCP-85-37.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Our knowledge of the effect of metformin on human health is increasing. In addition to its ability to improve the control of hyperglycaemia, metformin has been shown to reduce the burden o,f ageing via effects on damaged DNA and the process of apoptosis. Studies have shown that metformin may reduce the risk of cardiovascular disease through influences on body weight, blood pressure, cholesterol levels and the progression of atherosclerosis. Studies also suggest that metformin may be beneficial for neuro‐psychiatric disorders, cognitive impairment and in reducing the risk of dementia, erectile dysfunction and Duchenne muscular dystrophy. <italic>In vivo</italic> and <italic>in vitro</italic> studies have shown that metformin has anti‐cancer properties, and population studies have suggested that metformin may reduce the risk of cancer or improve cancer prognosis. It is thought that it exerts its anti‐cancer effect through the inhibition of the mammalian target of rapamycin (mTOR) signalling pathway. Because of its effect on the mTOR pathway, there may be a role for metformin in slowing or reversing growth of life‐threatening hamartomas in tuberous sclerosis complex.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="bcp13780-kwd-0001">clinical pharmacology</kwd>
<kwd id="bcp13780-kwd-0002">genetic polymorphism</kwd>
<kwd id="bcp13780-kwd-0003">genetics and pharmacogenetics</kwd>
<kwd id="bcp13780-kwd-0004">neurology</kwd>
<kwd id="bcp13780-kwd-0005">therapeutics</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<page-count count="10"></page-count>
<word-count count="5698"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bcp13780</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.4 mode:remove_FC converted:21.12.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bcp13780-cit-0000" publication-type="journal">
<string-name>
<surname>Amin</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lux</surname>, <given-names>A.</given-names>
</string-name>, and <string-name>
<surname>O'Callaghan</surname>, <given-names>F.</given-names>
</string-name> (<year>2019</year>) <article-title>The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth</article-title>. <source xml:lang="en"/>Br J Clin Pharmacol, <volume>85</volume>: <fpage>37</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.13780</pub-id>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>